andrew isidoridy: evaluating immunogenicity risk of complex peptide products
Published 1 year ago • 173 plays • Length 16:08Download video MP4
Download video MP3
Similar videos
-
5:59
evaluating immunogenicity risk of complex peptide products
-
52:05
timothy hickling: immunogenicity of biotherapeutics: why do we care and where do we stand
-
36:04
daron forman: the use of immunogenicity risk assessment tools for lead optimization of biologics
-
51:29
andrea ferrante: in-silico prediction of immunogenicity: filling the gaps
-
7:10
an integrated approach and strategies to mitigate immunogenicity risk
-
14:24
the finance of immunogenicity
-
36:09
susan kirshner fda: therapeutic proteins: routes of exposure and the risk of immunogenicity
-
22:34
proimmune t cell proliferation assays
-
25:50
what are antibody functions? do anti-drug antibodies have the same functions?
-
1:21:47
general principles clinical interpretation of immunogenicity
-
14:33
model informed drug development approaches for immunogenicity assessments workshop
-
29:19
sophie tourdot: non-clinical immunogenicity risk assessment of therapeutic proteins
-
29:22
bernd schlereth: mastering pharmacokinetics and immunogenicity of bispecific antibodies
-
1:28:25
immunogenicity information in labeling
-
33:50
2022 immunogenicity 101 how and when the immune system reacts to drugs
-
24:58
steven nadler: centyrin: sirna conjugates – a novel modality for the treatment of human disease
-
57:48
david wraith: unwanted immunogenicity: the design and development of tolerogenic t cell epitopes
-
7:37
immunogenicity -properties determining immunogenicity of a substance (fl-immuno/21)
-
36:47
robin thorpe: european regulatory guidance for unwanted immunogenicity
-
16:29
peng li: immunogenicity assessment during the development of antibody therapeutics
-
0:58
bonnie feldman: "it takes the average autoimmune patient 3.5 years to get a diagnosis."
-
2:23
einstein researcher leads national vaccine & therapy effort against potential pandemic viruses